Retatrutide

Evidence Anchor

BioHarmony 5.6/10

Retatrutide is a 5.6 / 10 fit for people following obesity, diabetes, liver-fat, or cardiometabolic drug development under medical supervision, because retatrutide has unusually large Phase 2 metabolic effects, but it is still investigational. [Jastreboff 2023](https://pubmed.ncbi.nlm.nih.gov/37366315/) gives the strongest anchor, while [Rosenstock 2023](https://pubmed.ncbi.nlm.nih.gov/37385280/) adds useful context without closing the case. The honest gap is simple: long-term safety, muscle preservation, discontinuation effects, and real-world sourcing remain unsettled. That puts Retatrutide in the tracked-experiment category, not the automatic-staple category. In practice, Retatrutide makes the most sense when you monitor body composition, glucose, liver fat, blood pressure, GI symptoms, gallbladder risk, and lean mass and avoid treating Retatrutide like an approved or casual peptide shortcut. ✅ Best for: Retatrutide is best for adults in Lilly-run clinical trials with severe obesity or obesity plus type 2 diabetes, MASLD/MASH, obstructive sleep apnea, knee osteoarthritis, or cardiovascular risk, where manufactured product, titration, laboratory monitoring, and adverse-event tracking are built in. If retatrutide receives FDA approval with a clean label, the strongest fit will be metabolically high-risk obesity after standard lifestyle work and approved alternatives have been considered. It is also best paired with resistance training, 1.6+ g/kg protein when clinically appropriate, and active monitoring for gallbladder, pancreatic, heart-rate, glucose, and lean-mass issues. ❌ Avoid if: Avoid retatrutide if you are sourcing research peptide online, treating it as a cosmetic cut, or using it for longevity microdosing. Avoid without specialist oversight if you have personal or family history of MTC or MEN2, prior pancreatitis, severe gastroparesis, active eating disorder, pregnancy plans, significant cardiovascular disease, advanced kidney disease, insulin or sulfonylurea use, or known diabetic retinopathy risk during rapid glucose improvement. Tested athletes should also treat retatrutide as high-risk under WADA S0 unless their sport authority confirms otherwise.

Read the full BioHarmony report

My score and my verdict: one signal of three, never the whole answer.